Compositions and methods for inhibiting expression of factor V
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsHans-Peter Vornlocher, John M. Maraganore
Life of this patent
Estimating the term…
Abstract
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of Factor V, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of Factor V. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of Factor V using the pharmaceutical composition; and methods for inhibiting the expression of Factor V in a cell.
Claims14
An isolated double-stranded ribonucleic acid (dsRNA) comprising a sense strand and an antisense strand and wherein the sense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:
- 5 and the antisense strand comprises at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:
- 6 respectively, wherein the dsRNA comprises a duplex structure at least 15 base pairs in length;
- and wherein the sense strand and the antisense strand are between 15 and 30 base pairs in length.
Dependencies are inferred from the claim text.